Journal of Korean Biological Nursing Science

  • 제22권2호
  • /
  • Pages.71-80
  • /
  • 2020
  • /
  • 2383-6415(pISSN)
  • /
  • 2383-6423(eISSN)
한국기초간호학회 (Korean society of Biological Nursing Science)
권호 표지
DOI QR코드

DOI QR Code

성인 남성의 혈청 테스토스테론 농도와 전립선 특이항원의 관계에 대한 통합적 고찰

The Relationship Between Levels of Serum Testosterone and Prostate-specific Antigen in Healthy Men: An Integrative Review

  • 투고 : 2020.04.04
  • 심사 : 2020.04.29
  • 발행 : 2020.05.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: The purpose of this study was to review primary research exploring the correlations between the levels of serum testosterone and the prostate-specific antigen (PSA) in healthy men without prostate diseases. Methods: An integrative review was conducted using the Whittemore & Knafle (2005) framework. The keywords, 'testosterone & prostate-specific antigen', 'testosterone & PSA' and 'healthy men' were used to search peer-reviewed publications in six databases. Among 1,959 searched articles, eleven articles were selected after excluding articles that do not meet inclusion criteria. Literature quality was moderate (Level 3). Results: As a result of this study, it was confirmed through the nine articles that healthy adult men showed no significant correlation between the serum testosterone and the PSA. Conversely, two articles presented that the serum PSA correlate positively with the testosterone. In particular, it is inferred that the effect of the serum testosterone and the PSA secreted into a 24-hour circadian rhythm with different amplitudes and slopes would have had great influence. However, it does not consider the factors affecting the testosterone and the PSA, such as race, liver disease, and BMI, so there is insufficient empirical data to clearly explain the relationship between the testosterone and the PSA. Conclusion: The correlation between the serum testosterone and the PSA in healthy adult men is insignificant in relation to the circadian rhythm of the testosterone and the PSA secretion. It is that a large-scale study including various influencing factors using new biochemical indicators such as pro PSA be conducted in the future.

키워드

참고문헌

  1. National Cancer Information Center. Annual report on the prevalences of cancer [Internet]. Goyang: National Cancer Center; 2020 [cited 2020 Feb 22]. Available from https://www.cancer.go.kr/lay1/S1T639C641/contents.do
  2. Wichendu PN, Odum EP, Amdi C, Aleme BM. Endogenous testosterone to prostate-specific antigen relationship in men without prostatic disease: a 10-year retrospective study. International Surgery Journal. 2018;5(4):1186-1191. https://doi.org/10.18203/2349-2902.isj20181099
  3. Gurbuz C, Canat L, Atis G, Guner B, Caskurlu T. The role of serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. Kaohsiung Journal of Medical Sciences. 2012;28:649-653. https://doi.org/10.1016/j.kjms.2012.02.003
  4. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006. 68(6):1263-1267. https://doi.org/10.1016/j.urology.2006.08.1058
  5. Koo JM, Shim BS. Significance of serum testosterone for prostate-specific antigen (PSA) elevation and prediction of prostate cancer in patients with PSA above 10 ng/ml. Korean Journal of Urology. 2010;51:831-835. https://doi.org/10.4111/kju.2010.51.12.831
  6. Boyle P, Koechlin A, Bota M, d'Onofrio A, Zaridze DG, Perrin P, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU International. 2016;118:731-741. https://doi.org/10.1111/bju.13417
  7. Walsh TJ, Shores MM, Krakauer CA, Forsberg CW, Fox AE, Moore KP, et al. Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels. Plos One 2018;13(6):e0199194. https://doi.org/10.1371/journal.pone.0199194
  8. Morote J, Ramirez C, Gomez E, Planas J, Raventos CX, de Torres IM, et al. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU International. 2009;104:486-9. https://doi.org/10.1111/j.1464-410X.2009.08378.x
  9. Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A. et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001;47:52-58. https://doi.org/10.1002/pros.1046
  10. Albisinni S, De Nunzio C, Tubaro A, Barry WT, Banez LL, Freedland SJ. Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy. Urology. 2012;80(1):162-167. https://doi.org/10.1016/j.urology.2012.01.068
  11. Rastrelli G, Corona G, Vignozzi L, Maseroli E, Silveril A, Monami M et al. Serum PSA as a predictor of testosterone deficiency. Journal of Sex Medicine. 2013;10:2518-2528. https://doi.org/10.1111/jsm.12266
  12. Albuquerque GAML, Guglielmetti GB, Barbosa JABA, Pontes Jr. J, Fazoli AJC, Cordeiro MD et al. Low serum testosterone is a predictor of high-grade disease in patient with prostate cancer. Revista da Associacao Medica Brasileira. 2017;63(8):704-710. https://doi.org/10.1590/1706-9282.63.08.704
  13. Arunprasad K, Chandramohan. Association between low serum testosterone and prostate cancer behaviour. International Journal of Contemporary Medical Research. 2018;5(8):H1-H4. https://doi.org/10.21276/ijcmr.2018.5.8.3
  14. Favilla V, Cimino S, Castelli T, Madonia M, Barbagallo I. Morgia G. Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. BJU International. 2010;106:1700-1703. https://doi.org/10.1111/j.1464-410X.2010.09459.x
  15. McLaren D, Siemens DR, Izard J, Black A, Morales A. Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome. BJU International. 2008;102(9):1142-1146. https://doi.org/10.1111/j.1464-410X.2008.07811.x.
  16. Haider A, Zitzmann M, Doros G, Isbam H, Hammerer P, Yassin A. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median follow up of 3 registries. Journal of Urology. 2016;193(1):80-86. https://doi.org/10.1016/j.juro.2014.06.071
  17. Cooper CS, MacIndoe JH, Perry PJ, Yates WR, Williams RD, The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. Journal of Urology. 1996;156:438-441. https://doi.org/10.1097/00005392-199608000-00028
  18. Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. Journal of Andrology. 2002;23(6):922-926. https://doi.org/10.1002/j.1939-4640.2002.tb02351.x
  19. Whittemore R, Knafl K. The integrative review: updated methodology. Journal of Advanced Nursing. 2005;52(5):546-553. https://doi.org/10.1111/j.1365-2648.2005.03621.x
  20. Armola RR, Bourgault AM, Halm MA, Board RM, Bucher L, Harrington L et al. Upgrading the American Association of Critical-Care Nurses' evidence-leveling hierarchy. American Journal of Critical Care. 2009;18(5):405-409. https://doi.org/10.4037/ajcc2009170
  21. Mermall H, Sothern RB, Kanabrocki EL, Quadri SF, Bremner FW, Nemchausky BA, et al. Temporal (circadian) and functional relationship between prostate-specific antigen and testosterone in healthy men. Urology. 1995;46(1):45-53. https://doi.org/10.1016/S0090-4295(99)80157-5
  22. Mifsud A, Choon AT, Fang D, Yong EL. Proste-specific antigen, testosterone, sex-hormone binding globulin and androgen receptor CAG repeat polymorphisms in subfertile and normal men. Molecular Human Reproduction. 2001;7(11):1007-1013. https://doi.org/10.1093/molehr/7.11.1007
  23. Sofikerim M, Oruc O, Eskicorapci S, Guliyev F, Ozen H. Correlation of serum androgen and pituitary hormone levels with serum PSA less than 2.5ng/ml. The Scientific World Journal. 2007;7:1128-1133. https://doi.org/10.1100/tsw.2007.177
  24. Mustafa M, Celik M, Horsanali O, Horuz R, Kucukcan A. Relationship between serum PSA and testosterone levels in two different geographic regions of Turkey. Turkish Journal of Urology. 2011; 37: 9-13. https://doi.org/10.5152/tud.2011.002
  25. Mustafa M, Horuz R, Celik M, Kucukcan A. Is there an association between serum prostate-specific antigen values and serum testosterone levels in healthy men? Korean Journal of Urology. 2014;55:465-468. https://doi.org/10.4111/kju.2014.55.7.465
  26. Peskoe SB, Joshu CE, Rohrmann S, McGlynn KA, Nyante SJ, Bradwin G, et al. Circulating total testosterone and PSA concentrations in a nationally representive sample of men without a diagnosis of prostatic cancer. Prostate. 2015;75(11):1167-1176. https://doi.org/10.1002/pros.22998
  27. Mustafa M, Nurigorgel S, Horsanali O, Abu Khadija HA, Marashde OM. PSA and testosterone serum levels in the Middle east: Is there a difference? Journal of Urology and Research. 2015;2(2):1028-1031.
  28. Elzanaty S, Rezanezhad B, Dohle G. Association between serum testosterone and PSA levels in middle-aged healthy men from the general population. Current Urology. 2016;10:40-44. https://doi.org/10.1159/000447149
  29. Shin YS, You JH, Cha JS, Park JK. The relationship between serum total testosterone and free testosterone levels with serum hemoglobin and hematocrit levels: a study in 1221 men. Aging Male. 2016;19(4):209-214. https://doi.org/10.1080/13685538.2016.1229764
  30. Shukla A, Sharda B, Sharma S, Bhardwaj S, Kailash U, Kalani R, et al.. Association between serum testosterone and serum PSA among men with and without partial androgen deficiency. Indian Journal of Clinical Biochemistry. 2020;35(1):127-131. https://doi.org/10.1007/s12291-018-0785-3
  31. Morgentaler A. Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. European Urology. 2009;55(2):310-321. https://doi.org/10.1016/j.eururo.2008.09.024
  32. Plymate SR, Tenover JS, Bremner WJ. Circadian variation in testosterone, sex hormone -binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young men and elderly men. Journal of Andrology. 1989;10(5):366-371. https://doi.org/10.1002/j.1939-4640.1989.tb00120.x
  33. Shea JL, Wong PY, Chen Y. Free testosterone: clinical utility and important analytical aspects of measurement. Advances in Clinical Chemistry. 2014;63:59-84. https://doi.org/10.1016/b978-0-12-800094-6.00002-9
  34. Choi YD, Kang DR, Nam CM, Kim YS, Cho SY, Kim SJ, et al. Age-specific prostate-specific antigen reference ranges in Korean men. Urology. 2007;70(6):1113-1116. https://doi.org/10.1016/j.urology.2007.07.063
  35. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology. 1996;48:55-61. https://doi.org/10.1016/s0090-4295(96)00611-5
  36. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. Journal of Urology. 1994;151(6):1571-1574. https://doi.org/10.1016/s0022-5347(17)35304-1
  37. Kilic S, Yalcinkaya S, Guntekin E, Kukul E, Deger N, Sevuk M. Determination of the site of metabolism of total, free, and complexed prostate-specific antigen. Urology. 1998;52(3):470-473. https://doi.org/10.1016/s0090-4295(98)00208-8
  38. Vicentini FC, Botelho LA, Hisano M, Ebaid GX, Lucon M, Lucon AM, et al. Are total prostate-specific antigen serum levels in cirrhotic men different from those in normal men? Urology. 2009;73(5):1032-1035. https://doi.org/10.1016/j.urology.2009.01.015
  39. Akdogan M, Hassoun BS, Guraker A, El-Sahwi K, Jazzar A. Wright H. et al. Prostate-specific antigen levels among cirrhotic patients. International Journal of Biological Markers. 2002;17:161-164. https://doi.org/10.1177/172460080201700303
  40. Zhang J, Ma M, Nan X. Sheng B. Obesity inversly correlates with prostate-specific antigen levels in a population with normal screening results of prostate cancer in northwestern China. Brazillian Journal of Medical and Biological Research. 2016;49(8):e5272. https://doi.org/10.1590/1414-431X20165272
  41. Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implication. European Urology. 2014;65(1):115-123. https://doi.org/10.1016/j.eururo.2013.08.015